Skip to content
Triangle logo TriangleGet started
← Study library

NCT03606174 · REGISTRY CONDITION SEARCH

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2023-08-24

The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Objective Response Rate (ORR)

→

outcome · POSTED

Number of Participants Who Experienced an Adverse Event (AE)

→

outcome · POSTED

Number of Participants Who Experienced a Serious Adverse Event (SAE)

→

outcome · POSTED

Number of Participants Who Experienced a Treatment-related Adverse Event

→

outcome · POSTED

Duration of Response (DOR)

→

outcome · POSTED

Clinical Benefit Rate (CBR)

→

outcome · POSTED

Progression-Free Survival (PFS)

→

outcome · POSTED

1-Year Survival Rate

→

outcome · POSTED

Overall Survival (OS)

→

outcome · POSTED

Geometric Mean Blood Plasma Concentration of Sitravatinib

→

outcome · POSTED

Cohort 9 Lead-in Dose Escalation Part Only: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Diagnosis of urothelial carcinoma * Adequate bone marrow and organ function Exclusion Criteria: * Uncontrolled tumor in the brain * Unacceptable toxicity with prior checkpoint inhibitor * Impaired heart function
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
    intervention Names
    1. Drug: Sitravatinib
    2. Drug: Nivolumab
    label
    Cohort 1
    type
    EXPERIMENTAL
  2. description
    Patients previously treated with checkpoint inhibitor, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
    intervention Names
    1. Drug: Sitravatinib
    2. Drug: Nivolumab
    label
    Cohort 2
    type
    EXPERIMENTAL
  3. description
    Patients previously treated with selected immunotherapies and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
    intervention Names
    1. Drug: Sitravatinib
    2. Drug: Nivolumab
    label
    Cohort 3
    type
    EXPERIMENTAL
  4. description
    Patients previously treated with with selected immunotherapies, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
    intervention Names
    1. Drug: Sitravatinib
    2. Drug: Nivolumab
    label
    Cohort 4
    type
    EXPERIMENTAL
  5. description
    Patients previously treated with platinum-based chemotherapy, but never treated with checkpoint inhibitor. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
    intervention Names
    1. Drug: Sitravatinib
    2. Drug: Nivolumab
    label
    Cohort 5
    type
    EXPERIMENTAL
  6. description
    Patients ineligible for treatment with platinum-based chemotherapy and never treated with checkpoint inhibitor. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
    intervention Names
    1. Drug: Sitravatinib
    2. Drug: Nivolumab
    label
    Cohort 6
    type
    EXPERIMENTAL
  7. description
    Patients previously treated with antibody-drug conjugate, checkpoint inhibitor and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
    intervention Names
    1. Drug: Sitravatinib
    2. Drug: Nivolumab
    label
    Cohort 7
    type
    EXPERIMENTAL
  8. description
    Patients previously treated with antibody-drug conjugate and checkpoint inhibitor, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
    intervention Names
    1. Drug: Sitravatinib
    2. Drug: Nivolumab
    label
    Cohort 8
    type
    EXPERIMENTAL
  9. description
    Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. There are 2 parts to this Cohort - a lead-in dose escalation portion and a dose expansion portion. In the dose escalation portion, treatment with up to 3 dose levels of sitravatinib in combination with up to 2 dose levels of pembrolizumab and enfortumab combination regimen to determine the recommended doses to be used in the combination treatment regimen and those doses will be further studied in the dose expansion portion. Pembrolizumab 200 mg over 30 min IV infusion every 3 weeks, sitravatinib orally once per day continuously in 21-day cycles (at 35 mg, 50 mg, 70 mg, or 100 mg) and enfortumab vedotin over 30 min IV infusion on Day 1 and Day 8 in 21-day cycles (at 1 mg/kg or 1.25 mg/kg).
    intervention Names
    1. Drug: Sitravatinib
    2. Drug: Pembrolizumab
    3. Drug: Enfortumab vedotin
    label
    Cohort 9
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Cohort 1
    2. Cohort 2
    3. Cohort 3
    4. Cohort 4
    5. Cohort 5
    6. Cohort 6
    7. Cohort 7
    8. Cohort 8
    9. Cohort 9
    description
    Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
    name
    Sitravatinib
    other Names
    1. MGCD516
    type
    DRUG
  2. arm Group Labels
    1. Cohort 1
    2. Cohort 2
    3. Cohort 3
    4. Cohort 4
    5. Cohort 5
    6. Cohort 6
    7. Cohort 7
    8. Cohort 8
    description
    Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
    name
    Nivolumab
    other Names
    1. Opdivo
    type
    DRUG
  3. arm Group Labels
    1. Cohort 9
    description
    Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
    name
    Pembrolizumab
    other Names
    1. Keytruda
    type
    DRUG
  4. arm Group Labels
    1. Cohort 9
    description
    Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
    name
    Enfortumab vedotin
    other Names
    1. Padcev
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
PARALLEL
intervention Model Description
There are 9 cohorts (having 9-55 maximum patients enrolled in each; based upon response rate). Patients are assigned to cohorts based upon their prior treatments for urothelial carcinoma.
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
260
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    ORR was defined as the number of participants documented to have a confirmed investigator-assessed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) V1.1. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must have decreased to normal size (short axis \< 10 mm). PR was defined as a greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.
    measure
    Objective Response Rate (ORR)
    time Frame
    Up to approximately 3 years
secondary Outcomes
  1. description
    An AE was defined as any reaction, side effect or other undesirable medical event that occurred during participation in a clinical trial, regardless of treatment group or suspected causal relationship to study treatment. Any clinically significant changes from baseline in laboratory results were recorded as AEs.
    measure
    Number of Participants Who Experienced an Adverse Event (AE)
    time Frame
    Day 1 up to approximately 3 years
  2. description
    An SAE was defined as any event that resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/permanent damage (substantial disruption of the ability to conduct normal life functions), a congenital anomaly/birth defect, or may have jeopardized the participant and may have required medical or surgical intervention to prevent intensive treatment in an emergency room or at home (e.g. for allergic bronchospasm, blood dyscrasias or convulsions) that do not result in inpatient hospitalization, development of drug dependency or drug abuse.
    measure
    Number of Participants Who Experienced a Serious Adverse Event (SAE)
    time Frame
    Day 1 up to approximately 3 years
  3. description
    A treatment-related adverse event was defined as an adverse event determined to have a possible causal relationship to the study treatment(s) by the investigator. An adverse event was defined as any reaction, side effect or other undesirable medical event that occurred during participation in a clinical trial. Any clinically significant changes from baseline in laboratory results were recorded as adverse events.
    measure
    Number of Participants Who Experienced a Treatment-related Adverse Event
    time Frame
    Day 1 up to approximately 3 years
  4. description
    DOR was defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of objective progression of disease (PD) per RECIST V1.1, or to death due to any cause in the absence of documented PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must have decreased to normal size (short axis \< 10 mm). PR was defined as a greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm. Per the statistical analysis plan (SAP), Cohort 9 arms are grouped as pre-specified as there was never intent to compare efficacy endpoints across Cohort 9 dose levels.
    measure
    Duration of Response (DOR)
    time Frame
    Up to approximately 3 years
  5. description
    Clinical Benefit Rate (CBR) was defined as the number of participants documented to have a confirmed CR, PR, or stable disease (SD), per RECIST V1.1, documented during at least 1 on-study assessment. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must have decreased to normal size (short axis \< 10 mm). PR was defined as a greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. SD was defined as target lesions increasing by less than 20% from the nadir, but enough that a previously documented 30% decrease no longer holds.
    measure
    Clinical Benefit Rate (CBR)
    time Frame
    Up to approximately 3 years
  6. description
    PFS was defined as the time from date of first study treatment to first PD per RECIST V1.1, or death due to any cause in the absence of documented PD.
    measure
    Progression-Free Survival (PFS)
    time Frame
    Up to approximately 3 years
  7. description
    Survival was defined as the time from date of first study treatment to death due to any cause. Kaplan-Meier (product limit) estimates of the percentage of participants who died at 1-year was calculated to estimate the 1-year survival rate, defined as the percentage of participants alive at 1 year. Confidence Intervals were calculated based on Greenwood's formula. Participants who discontinued prior to 1-year were censored on the last date that they were known to be alive. For participants with no follow-up after first dose of study drug, survival rate was censored at the date of first dose (Day 1).
    measure
    1-Year Survival Rate
    time Frame
    1 year
  8. description
    OS was defined as the time from date of first study treatment to death due to any cause.
    measure
    Overall Survival (OS)
    time Frame
    Up to approximately 3 years
  9. description
    Blood draws for analysis of blood plasma concentrations of sitravatinib were collected following electrocardiograms and assessment of vital signs. Concentration data below the limit of quantification were set to 0.
    measure
    Geometric Mean Blood Plasma Concentration of Sitravatinib
    time Frame
    Cycle(C)1 Day(D)1 pre-dose, 30min, 2,4,6,7,8,24hr post-dose, C1D15 pre-dose, 30min,2,4,6,7,8,24hr post-dose, C2D1 pre-dose,7hr post-dose, C2D8,C3D1,C3D8,C5D1,C6D8 pre-dose (28 day cycles Cohorts 1-8, 21 day cycles Cohort 9)
  10. description
    A DLT was defined as any of the following events considered to be causally related to treatment with sitravatinib in combination with pembrolizumab and enfortumab in the lead-in dose escalation part of Cohort 9 (as pre-specified): hematological DLTs (Grade 4 neutropenia, thrombocytopenia, anemia unexplained by underlying disease, ≥Grade 3 febrile neutropenia or neutropenia with significant clinical sequelae, or any requirement for a platelet transfusion), non-hematological DLTs (≥Grade 4 infusion related reaction, non-hematological toxicity, Grade 3 infusion related reaction that does not resolve within 24 hours, hypertension that cannot be controlled with medical therapy), other Grade 3 non-hematologic toxicity lasting for \>3 days, with exceptions, Grade 2 pneumonitis or colitis, ≥Grade 3 non-hematological laboratory abnormalities, alanine transaminase\>3 x upper limit of normal (ULN) with bilirubin\> 2xULN, and other related toxic effects may have been assessed as DLTs.
    measure
    Cohort 9 Lead-in Dose Escalation Part Only: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)
    time Frame
    Cycle 1 Day 1 through pre-dose Cycle 2 Day 1 (cycle for Cohort 9 was 21 days)
Full study description
brief Summary
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
detailed Description
Sitravatinib is an orally-available, small molecule inhibitor of a closely related spectrum of receptor tyrosine kinases (RTKs) including MET, Axl, MERTK, VEGFR family, PDGFR family, KIT, FLT3, Trk family, RET, DDR2 and selected Eph family members. Nivolumab is a human IgG monoclonal antibody that binds to the programmed cell death-1(PD-1) receptor and blocks its interaction with programmed cell death ligand-1 (PD-L1) and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response including anti-tumor immune response. Combining an immunotherapeutic PD-L1 checkpoint inhibitor with an agent that has both immune modulatory and antitumor properties could enhance the antitumor efficacy observed with either agent alone. Sitravatinib selectively inhibits key molecular and cellular pathways strongly implicated in checkpoint inhibitor resistance and therefore represents a rational strategy to enhance or restore anti-tumor immunity when combined with nivolumab, a checkpoint inhibitor therapy. Pembrolizumab is a humanized IgG4 monoclonal antibody that binds to the PD-1 receptor and selectively blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Enfortumab vedotin (enfortumab) is an investigational ADC that is comprised of a fully human anti-Nectin-4 IgG1 monoclonal antibody conjugated to MMAE via a protease-cleavable linker. Enfortumab binds to cells that express Nectin-4 with high affinity, triggering the internalization and release of MMAE in target cells, inducing cell cycle arrest and apoptotic cell death. Early efficacy results from enfortumab in combination with pembrolizumab in frontline cisplatin-ineligible urothelial carcinoma in the ongoing EV-103 study have demonstrated encouraging activity with a safety profile that appears manageable and tolerable. Addition of sitravatinib to this combination might further augment clinical activity by selectively inhibiting key molecular and cellular pathways strongly implicated in checkpoint inhibitor resistance.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-35a1659bc738f7160b49
      requested nct id
      NCT03606174
      primary nct id
      NCT03606174
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      308f79635904744c3081b7bece1bbf864685110f5917c0840a211e0e58d7fefc
      payload sha256
      ca1f7ebe2a24b8585aa678e81c0c6e0a5ffe47a8af067b24bf4148847e3319c9
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-35a1659bc738f7160b49
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03606174
      occurrences
      1. context exact
        NCT03606174
        end
        11
        exact text
        NCT03606174
        start
        0
      offset unit
      unicode_code_points
      query cond
      Urethral Cancer
      query disease state id
      ds-urethral-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-urethral-cancer-000.json
      source file sha256
      308f79635904744c3081b7bece1bbf864685110f5917c0840a211e0e58d7fefc
      source json pointer
      /studies/1/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      9071a53cfb313ec8756312c325bb58d64b26d8b3d20cf638590928af30f65474

    Preserved source evidence · Not medical advice